OSL oncosil medical ltd

Ann: Positive Overall Survival data released at ASCO 2019 Chicago, page-6

  1. 250 Posts.
    lightbulb Created with Sketch. 9
    @placeboed you have to use the chemotherapy regime for the patients recruited. FOLFIRINOX is a very toxic chemotherapy, its a cocktail of 4 chemotherapies blended and is only used for the patients that are the healthiest, a small percentage of pancreatic patients so the Overall Survival data for this subset is higher.

    Most pancreatic cancer patients in Australia and US are now using Gemcitabine + Abraxane. Abraxane is chemotherapy with solvent that is less toxic of nano particles of human serum albium.

    Use of Abraxane shows a 8 month OS, a 6 week OS median advantage over Gemcitabine alone.
    https://www.ncbi.nlm.nih.gov/pubmed/29950811

    16 months OS for Gemcitabine + Abraxane + OncoSil is big news for the oncology community.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.02
Change
0.020(2.00%)
Mkt cap ! $14.50M
Open High Low Value Volume
$1.00 $1.04 99.5¢ $44.55K 44.45K

Buyers (Bids)

No. Vol. Price($)
1 192 $1.03
 

Sellers (Offers)

Price($) Vol. No.
$1.04 6234 1
View Market Depth
Last trade - 15.48pm 25/06/2025 (20 minute delay) ?
OSL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.